Navigation Links
China-Biotics, Inc. Supplies Probiotics as Additive for Poultry Feed
Date:4/22/2009

SHANGHAI, April 22 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has signed an agreement with Dabeinong Group ("Dabeinong") to supply probiotics as bulk additives for poultry feed products.

Under the initial purchase order, which has already begun shipping, China-Biotics will provide probiotics such as lactobacillus acidophilus and streptococcus faecalis. These bulk additives will be used in several of Dabeinong's products and will help enhance the avian immune system and increase poultry survival and egg production rates in commercially raised poultry.

"We are delighted to supply probiotics to the poultry feed industry for the first time," said Mr. Jinan Song, China-Biotics' Chairman and Chief Executive Officer. "This agreement allows China-Biotics to enter an important new market segment, which we believe could become a significant driver of future growth. Improving the health and safety of commercial poultry is of the utmost importance to the Chinese government, as well as increasingly health-conscious consumers. We continue to demonstrate the appeal of our strong product quality and prompt technical support, which is enabling us to increase our market share in China. We look forward to cultivating additional long-term relationships with new commercial partners as we continue to expand the number of commercial applications for probiotics."

Founded in 1993 and headquartered in Beijing, Dabeinong is engaged in manufacturing and distributing animal feed, pesticides, animal medicines, seed and bacterin. With 5,000 employees, Dabeinong operates more than 40 affiliated companies, 500 retail stores and 1,000 county-level agricultural training centers.

China-Biotics expects that the demand for probiotics from the poultry feed market in China will increase to up to 2,500 metric tons by 2010.

To date, the Company has established a wide variety of business relationships with commercial customers located in Beijing and Shanghai cities and Jiangsu, Jiangxi, Qinghai, Shaanxi, Shandong and Zhejiang provinces. These growing companies are among the leaders in the baked foods, dairy, poultry feed and pharmaceutical industries.

About Dabeinong Group

Founded in 1993 and headquartered in Beijing, Dabeinong Group ("Dabeinong") is engaged in manufacturing and distributing animal feed, pesticide, animal medicines, seed, and bacterin. With 5,000 employees, Dabeinong operates more than 40 affiliated companies, 500 retail stores, and 1,000 county-level agriculture training centers. For more information, please visit http://www.dbn.com.cn .

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

     CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Appoints New Chief Financial Officer
2. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
3. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
4. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
5. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
6. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
7. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
8. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
9. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... Delpor, ... a $224K grant from the National Institute of Mental Health (NIMH) for the further ... on Delpor’s PROZOR technology and is expected to deliver therapeutic levels of ...
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
Breaking Biology Technology:
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
(Date:2/16/2017)...  Genos, a community for personal genetic discovery ... Laboratory Accreditation from the College of American Pathologists ... that meet stringent requirements around quality, accuracy and ... "Genos is committed to maintaining the highest ... to be receiving CAP accreditation," said Jill ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):